Newsletter

Stay up to date on all things coronary artery disease. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Make a comment and share this article on your profile.

Write a comment for your publication

Successfully Shared!

View on my Profile

Is Our Microbiome a Predictor of Cardiac Risk?

September 11, 2019

Overview

The Is Our Microbiome a Predictor of Cardiac Risk? Study intends to see if there is a connection between a person’s microbiome (flora/bacteria in the gut) and risk of developing cardiovascular disease. To determine this, researchers will investigate inflammatory markers in the blood and the bacteria’s genome. The goal of the study is to see if changes to the gut bacteria might be able to help prevent cardiovascular disease.

 

Study Information

The study will enroll 200 participants and look at how food is digested in the gut bacteria and how that affects the development of atherosclerosis and cardiovascular disease. In the study, researchers will collect 50 cc blood and plasma during the angiogram. Two weeks later, researchers will also collect stool samples.

 

Inclusion Criteria

  • Ages 18+
  • Undergoing cardiac catheterization for suspected coronary artery disease

 

Exclusion Criteria

  • Patients currently on long-term antibiotics who cannot stop them for at least 2 weeks prior to providing a stool sample.
  • Patients on chronic laxatives who cannot stop for at least 2 weeks prior to stool collection.
  • Patients on probiotics and cannot stop for 2 weeks prior to giving a stool sample (yogurt is fine).
  • Patients who can’t provide a stool sample to Mayo Clinic utilizing Fed Ex overnight mail.
  • Patients who have had previous Coronary Artery Bypass Grafting procedure
  • Patients who have a colostomy
  • Transplant Patients

 

Location

Mayo Clinic

Rochester, Minnesota, United States, 55905

Contact: Diana Albers, CRC    507-255-6884 albers.diana2@mayo.edu  

Principal Investigator: Amir Lerman, MD 

 

Collaborators/Sponsors

Mayo Clinic

Principal Investigator: Amir Lerman, MD – Mayo Clinic

Clinical Trials

View All

Semaglutide Treatment On Coronary Progression

The Semaglutide Treatment On Coronary Progression (STOP) study aims to see…

Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease

The Assessment of Biomarkers in Patients With Decompensated Heart Failure…

Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography

The Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography…

Efficacy and Safety Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)

The Efficacy and Safety Study of 99mTc-ECDG in the Evaluation of Coronary…

Acute Vascular Response to Exercise in Women With Nonobstructive Coronary Artery Disease

The Acute Vascular Response to Exercise in Women With Nonobstructive Coronary Artery Disease study aims to research…

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

In the Coronary Atherosclerosis T1-Weighted Characterization (CATCH) study,…

Send this to a friend